Clinical trial
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
NCT02933801 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
- Lead sponsor
- Swiss Cancer Institute
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 31, 2017
- Completion date
- November 15, 2023
- Enrollment
- 92 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer, prostate cancer metastatic